Frontera Therapeutics' Hong Kong IPO Prospectus Expires After 6 Months, Company Has 12 IND Approvals

According to Zhitong Finance, Frontera Therapeutics' Hong Kong IPO prospectus, submitted on December 23, 2025, expired on June 23, 2026, after reaching the six-month validity period. UBS Securities Hong Kong Limited and Haitong International Capital Limited served as joint sponsors for the offering.

The biopharmaceutical company, founded in 2019, has obtained 12 IND approvals from China's NMPA and the FDA and successfully advanced three candidate drugs to Phase II clinical trials. Frontera Therapeutics focuses on developing innovative recombinant adeno-associated virus (rAAV) gene therapies for ophthalmologic and cardiovascular diseases.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments